Predicting GLP-1 Discontinuation From Pharmacy Claims
Published: | Updated:
|Articles|January 27, 2021
Supplements and Featured Publications
- The Role of Lipoprotein(a) As a Biomarker to Assess Cardiovascular Risk
The Role of Lipoprotein(a) As a Biomarker to Assess Cardiovascular Risk
Advertisement
This publication is sponsored by Novartis AG.
This Clinical Practice Brief provides an overview of the genetic cardiovascular risk biomarker lipoprotein a (Lp[a]), as well as its importance as an independent risk factor for cardiovascular disease, the prevalence of elevated Lp(a) levels among the global population, and recommendations for lipid management.
Advertisement
Related Content
Advertisement
Advertisement
Trending on AJMC
1
5 Things to Know About the FDA's Peptide Reversal
2
Moderna, Merck mRNA Cancer Vaccine Succeeds in Late-Stage Trial
3
FDA Approves First Orexin Agonist for Narcolepsy Type 1
4
Student Mental Health, Success Tied to Future Health and Affordability
5